E
ZyVersa Therapeutics, Inc. ZVSA
$0.792 -$0.009-1.12%
Recommendation
Sell
Prev Close
$0.801
Volume
34,496
Avg Vol (90D)
1,405,483
Market Cap
$1.88M
Dividend & Yield
--
52-Week Range
$0.8001 - $10.20
P/E (TTM)
--
EPS (TTM)
-$69.90
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E
Very Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Very Weak
Dividend Index
--
Headlines
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces ...
3/12/2025 - GuruFocus
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition
3/12/2025 - The Fly
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model
3/12/2025 - Globe Newswire
ZyVersa Therapeutics announces pricing of $2M private placement
3/6/2025 - Seeking Alpha - Healthcare
ZyVersa Therapeutics prices 2.1M shares at 95c in private placement
3/6/2025 - The Fly
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
3/6/2025 - GuruFocus
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
3/6/2025 - Globe Newswire
ZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibition
3/5/2025 - The Fly
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
3/5/2025 - Globe Newswire
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Decreases By 34.4%
12/28/2024 - Ticker Report
ZyVersa Therapeutics files to sell 1.64M shares of common stock for holders
12/20/2024 - TipRanks Financial Blog
ZyVersa Therapeutics files to sell 1.64M shares of common stock for holders
12/20/2024 - The Fly
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco
12/18/2024 - Globe Newswire
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Expands By 34.9%
12/15/2024 - Ticker Report
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update
11/30/2024 - Ticker Report
ZyVersa Therapeutics announces publication on ASC Inhibitor IC 100
11/20/2024 - The Fly
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC ...
11/20/2024 - GuruFocus
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
11/20/2024 - Globe Newswire
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc
11/15/2024 - GuruFocus
ZyVersa Therapeutics Reports Q3 Progress and Outlook
11/15/2024 - TipRanks Financial Blog
ZyVersa Therapeutics GAAP EPS of -$2.43 misses by $0.83
11/14/2024 - SeekingAlpha.com: All News
ZyVersa Therapeutics reports Q3 EPS ($2.43) vs ($30.18) last year
11/14/2024 - The Fly
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
11/14/2024 - Globe Newswire
ZyVersa Therapeutics highlights published data on islet beta cell function
11/5/2024 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$9.62M
EBIT (TTM)
-$9.63M
Net Income (TTM)
-$21.33M
Balance Sheet
Total Assets (Q)
$19.42M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$12.40M
Book Value Per Share (Q)
$6.54
Cash Flow
Cash from Operations (TTM)
-$9.12M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$7.67M
Net Change in Cash (TTM)
-$1.46M
Filings
Filing Date
Thursday, November 14, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.43
7-Day Total Return
-16.11%
30-Day Total Return
-42.61%
60-Day Total Return
-24.59%
90-Day Total Return
-60.60%
Year to Date Total Return
-27.34%
1-Year Total Return
-90.09%
2-Year Total Return
-99.89%
3-Year Total Return
-99.98%
5-Year Total Return
--
52-week Low
Mar 13, 2025 - $0.8001
52-week High
Mar 18, 2024 - $10.20
Valuation
Market Cap
$1.88M - Nano Cap
Enterprise Value
$1.75M
Price/Sales (TTM)
--
Price/Book (Q)
0.12
Dividends and Shares
Shares Outstanding
988.40K
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.zyversa.com
Phone Number
754 231 1688
Address
2200 N. Commerce Parkway
Weston, FL 33326
Country
United States
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug... more
NASDAQ 03/14/2025 12:14PM Eastern Quotes delayed
Weiss Ratings